CytomX Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.38
- Today's High:
- $1.41
- Open Price:
- $1.38
- 52W Low:
- $1.17
- 52W High:
- $3.02
- Prev. Close:
- $1.37
- Volume:
- 68310
Company Statistics
- Market Cap.:
- $111.45 million
- Book Value:
- -1.306
- Revenue TTM:
- $67.62 million
- Operating Margin TTM:
- -99.41%
- Gross Profit TTM:
- $53.16 million
- Profit Margin:
- -104.47%
- Return on Assets TTM:
- -15.81%
- Return on Equity TTM:
- -5475.03%
Company Profile
CytomX Therapeutics Inc had its IPO on 2015-10-08 under the ticker symbol CTMX.
The company operates in the Healthcare sector and Biotechnology industry. CytomX Therapeutics Inc has a staff strength of 116 employees.
Stock update
Shares of CytomX Therapeutics Inc opened at $1.38 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.38 - $1.41, and closed at $1.4.
This is a +2.19% increase from the previous day's closing price.
A total volume of 68,310 shares were traded at the close of the day’s session.
In the last one week, shares of CytomX Therapeutics Inc have slipped by -6.67%.
CytomX Therapeutics Inc's Key Ratios
CytomX Therapeutics Inc has a market cap of $111.45 million, indicating a price to book ratio of 3.8062 and a price to sales ratio of 1.4467.
In the last 12-months CytomX Therapeutics Inc’s revenue was $67.62 million with a gross profit of $53.16 million and an EBITDA of $-64790000. The EBITDA ratio measures CytomX Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CytomX Therapeutics Inc’s operating margin was -99.41% while its return on assets stood at -15.81% with a return of equity of -5475.03%.
In Q1, CytomX Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 159.9%.
CytomX Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -1.8
Its diluted EPS in the last 12-months stands at $-1.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -1.8. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CytomX Therapeutics Inc’s profitability.
CytomX Therapeutics Inc stock is trading at a EV to sales ratio of 0.7429 and a EV to EBITDA ratio of 0.6936. Its price to sales ratio in the trailing 12-months stood at 1.4467.
CytomX Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $234.63 million
- Total Liabilities
- $151.26 million
- Operating Cash Flow
- $-146642000.00
- Capital Expenditure
- $48000
- Dividend Payout Ratio
- 0%
CytomX Therapeutics Inc ended 2024 with $234.63 million in total assets and $0 in total liabilities. Its intangible assets were valued at $234.63 million while shareholder equity stood at $-86637000.00.
CytomX Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $151.26 million in other current liabilities, 1000.00 in common stock, $-726190000.00 in retained earnings and $949000.00 in goodwill. Its cash balance stood at $56.36 million and cash and short-term investments were $204.50 million. The company’s total short-term debt was $4,204,000 while long-term debt stood at $0.
CytomX Therapeutics Inc’s total current assets stands at $212.28 million while long-term investments were $0 and short-term investments were $148.15 million. Its net receivables were $1.09 million compared to accounts payable of $2.20 million and inventory worth $0.
In 2024, CytomX Therapeutics Inc's operating cash flow was $-146642000.00 while its capital expenditure stood at $48000.
Comparatively, CytomX Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.4
- 52-Week High
- $3.02
- 52-Week Low
- $1.17
- Analyst Target Price
- $2.52
CytomX Therapeutics Inc stock is currently trading at $1.4 per share. It touched a 52-week high of $3.02 and a 52-week low of $3.02. Analysts tracking the stock have a 12-month average target price of $2.52.
Its 50-day moving average was $1.64 and 200-day moving average was $1.84 The short ratio stood at 4.66 indicating a short percent outstanding of 0%.
Around 146.8% of the company’s stock are held by insiders while 5742% are held by institutions.
Frequently Asked Questions About CytomX Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.